Inicio › Mieloma múltiple › Virginia
Ensayos clínicos de Mieloma múltiple en Virginia
20 estudios sobre Mieloma múltiple buscan participantes en Virginia.
Ciudades en Virginia
Texto oficial del estudio (inglés)
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Virginia Cancer Specialists - Fairfax /ID# 268559, Fairfax
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT05650632A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Alexander T. Augusta Military Medical Center, Fort Belvoir
- Virginia Oncology Associates Brock Cancer Center, Norfolk
- Richmond VA Medical Center, Richmond
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05552222AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Fairfax
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT06106945Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- VCU Massey Comprehensive Cancer Center, Richmond
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT06465316A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Charlottesville
ReclutandoFase 3
Edades de 18 a 130 · Todos los sexos · Actualizado el 21 oct 2026 · NCT07735637A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Virginia Cancer Specialists - Fairfax /ID# 278716, Fairfax
- Blue Ridge Cancer Care - Roanoke /ID# 278722, Roanoke
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT07095452AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Charlottesville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 oct 2026 · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Virginia Oncology Associates, Norfolk
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 oct 2026 · NCT06297226A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Gainesville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07391657A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Charlottesville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07073547A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Virginia Commonwealth University - Massey Cancer Center, Richmond
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06500884TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Inova Schar Cancer Institute, Fairfax
ReclutandoFase 2
Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT02693535Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Fairfax
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT07764978Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Sovah Health Martinsville, Martinsville
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- y 2 más
ReclutandoFase 3
Todas las edades · Todos los sexos · Actualizado el 10 jun 2026 · NCT05561387Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Virginia Oncology Associates, Norfolk
ReclutandoFase 2
Edades de 19 en adelante · Todos los sexos · Actualizado el 4 jun 2026 · NCT06974786Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Virginia Cancer Specialists, Fairfax
- Blue Ridge Cancer Center, Roanoke
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 abr 2026 · NCT05972135A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Fairfax
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 abr 2026 · NCT06679101A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Norfolk
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 24 mar 2026 · NCT04988555CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Virginia Commonwealth University, Richmond
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2025 · NCT05722418IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- NEXT Oncology Virginia, Fairfax
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 jun 2025 · NCT06119685De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.